



PATENT  
930068-2002.R1.1

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Robert H. Keller et al.  
Application to  
Reissue Patent No. : 6,262,019  
Issued : July 17, 2001  
For : METHOD OF TREATING GLUTATHIONE DEFICIENT  
MAMMALS

REISSUE DECLARATION AND POWER OF ATTORNEY

Vit-Immune, L.C. and Applicants, Robert H. Keller and David W. Kirchenbaum  
hereby declare as follows:

1. The entire right, title and interest in the '019 patent is vested in Vit-Immune, L.C. by an assignment executed on April 29, 1999, by Robert H. Keller and David W. Kirchenbaum.
2. The '019 patent claims the benefit of provisional application 60/083,661 filed on April 30, 1998.
3. Applicant's residences, post office addresss and citizenships are as stated below next to their names.
4. Applicants verily believe ourselves to be original, first and joint inventors of the invention described and claimed in Letters Patent No. 6,262,019 and in the specification filec for which we solicit a patent.
5. Applicants hereby state that they have reviewed and understand the contents of the specification, including the claims.
6. Applicants acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).
7. Applicants acknowledge the duty to disclose to the U.S. Patent Office all

00283550

**BEST AVAILABLE COPY**

Express Mail No. EV713810567US

information known to Vit-Immune, L.C. to be material to patentability as defined in 37 C.F.R. § 1.56(a).

8. Applicants do not know and do not believe that the invention was ever known or used in the United States of America before our invention thereof.

9. Applicants verily believe the original Letters Patent to be wholly or partly inoperative or invalid by reason of Applicants claiming more or less than they had a right to claim in the patent.

10. Applicants did not discover that the claims of the original patent claimed more or less than we had a right to claim until after the original patent was issued.

11. All errors being corrected in this reissue application arose without any deceptive intention on Applicant's part.

12. New claim 34 submitted with this application particularly point out subject matter which Applicants considered to be their invention and round out the scope of protection to which Applicants are entitled. By the omission of such claims the original patent claims less than Applicant's had a right to claim. Applicants did not realize at the time the application was drafted that they had the right to additionally claim the method of promoting the biosynthesis of mucosal glycoproteins and/or facilitating the absorption of N-acetylcysteine into a gastrointestinal tract of a mammal, comprising the step of administering the composition of claim 1.

13. Applicants hereby appoint Ronald R. Santucci, Registration No. 28,988, of Frommer Lawrence & Haug LLP or their appointed associate(s) with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the U.S. Patent and Trademark Office and in the Courts in connection therewith, and specify that all communications about the application are to be directed to the following address:

00283550

BEST AVAILABLE COPY

PATENT  
930068-2002.R11

Ronald R. Santucci, Esq.  
c/o Frommer Lawrence & Haug LLP  
745 Fifth Avenue  
New York, New York 10151

Direct all telephone calls to: (212) 588-0800 to the attention of Ronald R. Santucci, Esq.

Applicants and Vit-Immune, L.C. hereby offers to surrender original U.S. Patent No. 6, 262, 019 and ask that Letters Patent may be reissued to Vit-Immune, L.C. for the same invention upon the attached specification.

Vit-Immune, L.C. and the undersigned applicants, further declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

David Kirshbaum  
Vit-Immune, L.C.

1-4-06  
Date

David Kirshbaum

By

President

Title:

Robert H. Keller

Robert H. Keller

Date

1/4/06

5401 W. Surt Rd. Hollywood FL 33019

Residence: 501 Ranch Road, Weston, Florida 33326

Citizenship: United States

00283550

BEST AVAILABLE COPY

*David Kirchenbaum*

David Kirchenbaum

*1-4-06*

Date

PATENT  
930068-2002.REI

Residence: ~~3272 Huntington, Weston, Florida, 33332~~

*8961 S.W. 6th Ave, Plantation, FL 33324-3730*

Citizenship: United States

Post Office Address of Inventors: *5821 Hollywood Blvd, Hollywood, FL 33021*

002835:0

BEST AVAILABLE COPY